Cabozantinib Shines in Kidney Cancer Treatment: Breakthroughs in Brain Mets and Aggressive Disease Subtype
A recent study has brought exciting news for patients with kidney cancer, particularly those with brain metastases and an aggressive disease subtype. The research, presented at the International Kidney Cancer Symposium, highlights the remarkable efficacy of cabozantinib (Cabometyx) in treating these challenging cases.
Brain Metastasis Progression and Response
In a small prospective study, 14 out of 25 patients with non-locally treated brain metastases from kidney cancer remained free of metastatic progression for at least 6 months after receiving cabozantinib. This translates to a 56% brain metastasis progression-free survival (PFS) rate at 6 months. Moreover, 61% of patients experienced partial responses, and 8% had stable disease. These findings indicate that cabozantinib could significantly improve outcomes for patients with brain metastases.
Extended Efficacy in Fumarate Hydratase-Deficient RCC
The study also revealed that cabozantinib, when combined with nivolumab (Opdivo), demonstrated a 71% response rate in fumarate hydratase-deficient renal cell carcinoma (FH-dRCC). This subtype of kidney cancer, which originates from mutations in the FH gene, has historically been challenging to treat. The combination of cabozantinib and nivolumab has shown promise, extending its efficacy beyond non-clear cell RCC, where it is already the preferred treatment.
CABRAMET Trial: Encouraging Results
The CABRAMET trial, a phase II multicenter study, further reinforces cabozantinib's potential. It enrolled 26 adults with metastatic RCC and non-locally treated brain metastases, treating them with cabozantinib. The primary endpoint was met, with a 6-month brain metastasis PFS rate of 56%. The overall response rate was 61%, with encouraging results across different treatment backgrounds.
FH-dRCC: A Rare but Aggressive Subtype
FH-dRCC, a rare subtype of RCC, has historically lacked effective treatments. However, recent studies have shown promising outcomes. The combination of erlotinib and bevacizumab has shown efficacy, but recurrence is common. Two combinations of immune checkpoint inhibitors and tyrosine kinase inhibitors (TKIs) have emerged as potential game-changers. Sintilimab and axitinib achieved an ORR of 56% and a median PFS of 19.8 months, while tislelizumab and lenvatinib led to an impressive 93% ORR and an ongoing response in most cases.
Conclusion and Future Directions
The studies presented at the International Kidney Cancer Symposium highlight cabozantinib's potential in treating kidney cancer, especially in challenging cases. The results suggest that cabozantinib could significantly improve outcomes for patients with brain metastases and FH-dRCC. However, further research is needed to determine the optimal TKI and IO combination and the best sequence of therapies for these aggressive disease subtypes.
This breakthrough research opens up new possibilities for patients with kidney cancer, offering hope for improved survival and quality of life. As the medical community continues to explore these treatments, patients can look forward to more personalized and effective care in the future.
